The polyglutamine (polyQ) repeat disorders are a family of inherited disorders characterized by progressive neurodegeneration, as well as the formation of intracellular protein aggregates. Huntington's disease (HD) is the most prevalent disorder in the family of polyQ diseases. This family includes nine other neurodegenerative disorders: Dentatorubral-pallidoluysian atrophy (DRPLA), Bulbo-Spinal Muscular Atrophy (BSMA) and Spinocerebellar ataxia (SCA) types 1-3, 6, 7, 12 and 17. Each disease is caused by the expansion of a tract of repeated CAG triplet in a distinct gene, causing transcription of proteins with lengthened polyQ repeats. Although mutations occur frequently in a ubiquitously expressed gene, neurodegeneration occurs in a specific cell type. The mutant proteins involved in polyQ disease are unrelated and they share only the glutamine extension. As for the pathogenic mechanism by wich the repeat expansion leads to the disease, major models include a loss of function of the gene and a gain of function by the mutant RNA transcript or protein product. Indeed, altered function in the ubiquitin-proteasome system (UPS), endoplasmic reticulum (ER) and mitochondria function, as well as a primary failure in autophagy has been demonstrated. However, the pathogenic mechanism varies from one disease to another, depending on the motif, length, and intragenic location of the repeat. Understanding the molecular mechanisms of repeat instability and pathogenic process is not only of scientific interest but also essential for the development of rational treatment of these diseases.
INTRODUCTION
Polyglutamine diseases are a group of pathologies in which the toxic aggregate-prone mutant protein contains an abnormally long stretch of glutamine (Q) residues in its sequence. Huntington's disease (HD) is one of the best characterised disorders among these polyglutamine-expanded diseases, which also include disorders such as bulbo-spinal muscular atrophy (BSMA), spinocerebellar ataxias, and dentatorubral-pallidoluysian atrophy (DRPLA). Although the genes (and proteins) involved in different polyQ diseases have little homology, these disorders share a striking relationship between their clinical manifestations and their genetic underpinning. Symptoms appear only if the length of the expanded tract exceeds a critical value of 35-45 glutamines, with a greater number of repeats leading to earlier disease onset and more severe manifestations [1] . Accordingly, it is hypothesized that neuronal toxicity present in polyQ diseases is derived from the polyQ expansion itself, which induces pathogenesis by a common molecular mechanism in these disorders [1] . Nevertheless, whereas pathogenesis is clearly triggered by the presence of the abnormal glutamine tract in each CAG disorder, the disease pathway in HD as in each CAG disorder may begin differently, a) through an effect on the function of the host protein, b) through an effect on existing or new interactions of the fulllength host protein, or c) through the process or consequences of forming insoluble polyQ amyloid. Thus, different pathways converge in a common feature and are closely linked in producing a specific neurodegeneration. The convergence of different pathways can explain the cellspecificity of the disease that affects the cellular type more *Address correspondence to this author at the Department of Neurological Sciences, Second University of Naples, Via Sergio Pansini 5, 80131 Napoli, Italy; Tel: +390815666810; Fax: +390815666805; E-mail: marina.melone@unina2.it sensitive to the combined effect of multiple pathways. Despite the individual intricacies of each neurodegenerative disorder, there are some common features, mostly those associated with the way in which neurons handle the presence of the altered proteins. Genetic and environmental factors can accelerate this process, whereas properly functioning cellular quality-control systems (molecular chaperones, ubiquitin-proteasome system (UPS), phagosome and lysosome system) limit the accumulation of misfolded proteins. Altered proteins that still maintain their solubility are normally targeted for degradation through either the ubiquitin-proteasome system or Chaperone-mediated autophagy (CMA). Degradation through these systems confers selectivity, allowing the elimination of the altered protein without consequences on neighbouring intracellular components. The criteria that determine delivery to one or another system are not clear, but it could be associated with the availability of each system at a given time or particular characteristics of the substrate. Indeed, altered function in the UPS, endoplasmic reticulum (ER) and mitochondria function, as well as a primary failure in autophagy has been demonstrated. On the basis of these observations various therapeutic approaches have been developed: among those, are included agents that increase the folding rate by inhibiting aggregation, as well as agents that modulate ER stress, reduce ROS formation, or manipulate macroautophagy, or degradation through UPS.
POLYGLUTAMINE (POLYQ) DISEASES
PolyQ diseases are caused by expansion of an unstable CAG repeat in the DNA coding sequences that is translated in an enlarged polyglutamine (PolyQ) domain in the disease protein. The mutant proteins involved in polyQ diseases are unrelated and they share only the glutamine extension. Clinical and neuropathological features are shown in Table 1 . The age at onset and severity of disease symptoms inversely correlate with the length of the glutamine repeat [1] ( Table 1) . Moreover, the presence of a polyQ tract in the disease protein leads to the formation of nuclear and cytoplasmtic aggregates [1] .
Huntington's disease (HD) is the most frequent of the polyQ diseases and it is produced by polyQ expansion in the huntingtin (Htt) protein. Wild-type Htt contains 11-34 glutamine repeats that start at amino acid 18 of the protein. Disease appears when the polyQ is over 37 glutamines. HD symptoms include psychiatric abnormalities (depression, irritability, apathy, anxiety), uncontrolled movements and mental deterioration [1] . Interestingly, HD patients show also hypothalamic dysfunction, leading to sleep disturbances, alteration in circadian rhythm and weight loss [2] . They also present endocrine changes resulting in increased prevalence of diabetes [2] . Although Htt is ubiquitously expressed, mutant Htt (mHtt) induces specific cell-type neurodegeneration prevalently in the striatum and deeper layers of the cortex at the early stages [3] . However, in the advanced stages of the disease other brain regions are affected, such as hippocampus, hypothalamus, amygdala, thalamic nuclei [4] . In HD, inclusions are the consequence of accumulation of unfolded mHtt. A characteristic of HD is the presence of mHtt aggregates in the nucleus or in the perinuclear region, while the wild type protein is mostly cytoplasmatic [1] . Moreover, cytoplasmatic aggregates are also found in neuronal process [1] . Nuclear aggregates are due to proteolytic cleavage of mHtt. Wild-type Htt may be involved in cellular vesicle trafficking, endocytosis, (see below) as well as in regulation of gene expression (Fig. 1) . Although traditionally considered a "gain-of-function" disease, the recent finding that wild-type Htt has an important role in neuronal survival suggests that "loss-of-function" of the normal protein might contribute to HD as well, also discloseing new perspectives on the therapeutical approach to the pathology.
The other autosomal dominant PolyQ diseases are: spinocerebellar ataxia (SCA) 1-3, 6, 7, 12, 17, dentatorubralpallidoluysian atrophy (DRPLA). Bulbo-Spinal Muscular Atrophy (BSMA; Kennedy's Syndrome) is an X-linked motor neuron disease caused by the expansion of a polyQ tract within the Androgen Receptor (AR) [5] . Autosomal dominant SCAs are neurodegenerative disorders characterized by loss of balance and motor coordination as consequence of dysfunction of the cerebellum and its afferent and efferent connections [6] . Only few SCA subtypes are characterized by expansion of CAG repeats located within the coding region and leading to an abnormally extended PolyQ tract [6] . These forms are: SCAs 1-3, 6, 7, 17, and DRPLA. The mutant disease proteins are ataxins 1, 2, and 3, alpha 1A-voltage-dependent calcium channel (CACN1A4), ataxin 7, TATA box binding protein and atrophin 1, respectively [6] . SCAs can show also associated symptoms such as ophtalmoplegia, pyramidal and extrapiramidal signs, dementia, pigmentary retinopathy and peripheral neuropathy [6] ( Table 1) . Clinical manifestations of DRPLA include chorea, a lack of coordination, ataxia, and dementia [6] . While DRPLA, SCA3 and HD never show interrupted CAG extension, in most SCA1 and SCA2 alleles the poly CAG sequence is interrupted by either CAT or CAA sequence, suggesting that these interruptions protect from the presence of nuclear protein aggregates produced by proteolytic cleavage of the polyQ stretch. It has been hypothesized that interruption inside the repeat inhibits the proteolytic cleavage, resulting in a less toxic mutant protein. Indeed, it has been found a SCA1 family carrying 45 repeat units but not affected by the disease and in good health. In this family the CAG repeat was interrupted leading to insertion of histidine in the PolyQ repeat [5] . SCA3, known also as Machado-Joseph disease (MJD), is one of the most prevalent autosomal dominant cerebellar ataxias. It is a neurodegenerative disease that starts during adulthood, with patients showing difficulties in gait, later becoming bedridden, and ultimately presenting premature death [6] . SCA6 is a neurodegenerative disorder caused by abnormal expansions of a trinucleotide CAG repeat in exon 47 of the CACNA1A4 gene, which encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel. It is the only one caused by small expansion of the CAG repeat (4-20 units). The CAG repeat expansion is translated into an elongated polyglutamine tract in the carboxyl terminus of the alpha1A subunit. The alpha1A subunit is the main pore-forming subunit of the P/Q-type calcium channel. Patients with SCA6 suffer from a severe form of progressive ataxia and cerebellar dysfunction [6] . It has been proposed that the molecular mechanisms leading to SCA6 differ despite the other PolyQ diseases and it is due to loss of function of the disease protein [5] . SCA7 is clinically unique in that it is the only polyglutamine disorder in which the retina is affected, eventually resulting in blindness. Insight into the molecular basis of SCA7 has come largely from studies on the function of ataxin-7 in rodphotoreceptors. Ataxin-7, the protein mutated in SCA7, is a subunit of the GCN5 histone acetyltransferase complexes TFTC (the TATA-binding protein-free TBP-associated factor-containing complex) and STAGA (the SPT3/TAF GCN5 complex). Indeed, rods uniquely require chromatin condensation for the proper level of expression of a set of genes required for rod differentiation and function [6] . SCA17 is a progressive neurodegenerative disease with an onset typically in midlife. In addition to ataxia, patients with SCA17 suffer from dementia and, in some cases, epilepsy. At a pathological level, SCA17 consists of marked cerebellum atrophy and, to a lesser extent, atrophy of the cerebral cortex. SCA17 is caused by expansion of the glutamine tract beyond 42 in the TATA-box-binding protein (TBP).
DRPLA is a progressive neurodegenerative disease caused by the expansion of polyglutamine repeats within the atrophin-1 protein. Clinical manifestations of DRPLA include chorea, a lack of coordination, ataxia, and dementia [6] . In 1999, SCA12 was shown to be caused by a noncoding CAG repeat expansion [7] . In fact, the CAG extension is located 133 bp upstream the major transcription start site of the gene encoding the PR55beta subunit of protein phosphatase PP2A holoenzyme (PP2A-PR55beta also called PPP2R2B, PP2AB55beta or PP2ABbeta). PP2A is one of the major classes of Ser/Thr phosphatases with likely thousands of phospho-protein substrates. The expression of PR55beta is brain-specific. The exact relationship between the CAG repeat and the PPP2R2B transcript remains elusive. However, it has been demonstrated that there are at least one RNA transcript containing the CAG extended tract. It has been hypothesized that the CAG extension affects the expression of PR55beta, leading to altered function of PP2A, with changes in protein phosphorilation in the brain [7] . Alternatively, and because some forms of transcripts contain the CAG repeat, a second possible model involving a gain-offunction RNA mechanism is also possible [7] .
Bulbo-Spinal Muscular Atrophy (BSMA; Kennedy's Syndrome) is caused by expansion of a polyQ tract in the Androgen Receptor (AR) [8] . This disease affects only males, while females carrying the mutant alleles are usually asymptomatic. This disease is characterized by proximal muscular atrophy, weakness, contraction fasciculation and bulbar involvement [8] (Table 1) .
PATHOGENIC MECHANISMS

Formation of Aggregates
Abnormal protein conformation and protein aggregation are emerging as common features of the neurodegenerative diseases, such as polyQ diseases, and many indirect lines of evidence link aggregation to toxicity. However, other studies indicate that inclusion body formation can be disassociated from toxicity, and might represent a cellular protective response. For example in HD, inclusion bodies are present in the cells of the striatum, which undergoes massive degeneration, but are more dense in the cerebral cortex, which undergoes only moderate degeneration [for review see 9] . Moreover, striatal inclusion bodies are most prevalent in large interneurons, which are spared in HD, rather than in medium spiny neurons, which are selectively lost in the disease [9] . How can this apparent paradox be resolved: that the process of aggregation might be related to toxicity, but that the inclusion bodies might be protective? So, common refrain in neurodegenerative disease is the "toxic intermediates". There is increasing, although still indirect, evidence that inclusion bodies might represent an end-stage manifestation of a multistep aggregation process. Early events before the formation of inclusion bodies might cause toxicity. Protein aggregation is probably a complex multi-step process with several possible intermediate species, including oligomeric forms and protofibrillar forms. Particular molecular species could be responsible for toxicity -for example, monomers, oligomers, protofibrils or specific forms of fibrils. Alternatively, the early species in this process might be most toxic, perhaps through the exposure of buried moieties such as main chain NH and CO groups that could serve as hydrogen bond donors or acceptors in abnormal interactions with other cellular proteins. A more general proposal for the relationship between aggregation and toxicity is that toxicity depends on interactions with, and possibly recruitment of, other cellular constituents during the aggregation process. Therefore, perhaps no single species is toxic per se, but instead the active process of aggregation, and interactions with other proteins in the cell, causes toxicity.
Conversely, oxidative damage, UPS dysfunction or impairment of chaperone-mediated autophagy (CMA) can contribute to protein aggregation. Thus, different pathways converge in a common feature and are closely linked in producing a specific neurodegeneration ( Table 2 ).
Protein Trafficking
Alteration in protein trafficking is a common feature in neurodegeneration. Impaired vesicle trafficking occurs in HD. Wild type Htt is directly involved in protein trafficking and vesicular transport [1] . Indeed, Huntingtin-associated Protein 1 (HAP1) localizes in early endosomes and is involved in early to late endosome trafficking. HAP1 interacts with hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), which is involved in EGFR (epidermal growth factor receptor) endocytic trafficking [10] . Htt-associated protein 40 (HAP40) mediates the recruitment of Htt by Rab5 onto early endosomes [11] . Htt is involved in vesicle trafficking also through interaction with Rab8 and regulates cell morphology [11] . Conversely, mHtt affects protein trafficking through various mechanisms. HAP40 is over-expressed in HD [11] and mHtt affects cell morphology [12] . Htt associates with -tubulin and microtubules, suggesting that the accumulation of -tubulin in mHtt-containing aggregates can enhance the formation of these aggregates [13] . Huntingtininteracting protein 1 (HIP-1) is essential for clathrin-mediated endocytosis of AMPA receptors [14] . Moreover, HIP1 down-regulates NMDA receptor-dependent phosphorylation of Htt by promoting NMDA receptor internalization [15] . Htt interacts also with HIP14, involved in vesicles trafficking [16] and with PACSIN 1, involved in synaptic vesicles recycling [17] . Conversely, mHtt associates with SH3GL3 (SH3-domain GRB2-like 3) that regulates synaptic vesicle recycling through interaction with dynamin 1 [18] . Thus, mHtt can impair vesicle trafficking through several mechanisms: loss of function of the normal allelic form because mHtt bind and sequester wild type Htt inside the aggregates [19] ; gain of function of mHtt, such as interaction with SH3GL3; aggregates formed by mHtt that can exert a physically inhibi- (Fig. 1) . PolyQ disease proteins affect the morphology of the Golgi apparatus: both SCA2 and BSMA are also characterized by the presence of aggregates in the Golgi apparatus [21] . All these alterations in vesicle trafficking lead to impaired cellular function, such as impaired synaptic vesicle targeting and contribute in producing the clinical features of polyQ diseases.
Ubiquitin-Proteasome System (UPS)
The ubiquitin-proteasome system (UPS) targets several proteins for non-lysosomal degradation. The central mechanism of UPS is the covalent link of ubiquitin to target proteins, which are recognized by the 26S proteasome, an adenosine triphosphate-dependent, multi-catalytic protease. In the proteasome complex, the core protease is the 20S. The 26S proteasome is constituted by one 20S and two 19S regulatory particles [22] . Although HD is characterized also by nuclear aggregates polyubiquitinated produced by cleavage of mHtt, it is still debated whether the UPS play a role in HD development [23] . C-terminal Hsp70-interacting protein (CHIP) inhibits mHtt aggregation both in vitro and in vivo, suggesting that the proteasome system mediates HD development [24] . Indeed, mHtt interacts with several heat shock proteins [1] and CHIP links the quality control system with the UPS. It has been proposed that the proteasome activator REGgamma could impair UPS in HD, by blocking the proteasomal catalytic sites that cleaves Gln-Gln bonds. However, reduction of REGgamma in vivo does not affect the disease development in an HD animal model [25] . The heat shock, DnaJ-like-1 (HSJ1) proteins (which contain DnaJ and ubiquitin-interacting motifs) reduce polyQ aggregates, by increasing protein ubiquitination and promoting degradation through UPS [26] .
Ataxin 3 is an ubiquitin-specific cysteine protease that associates with the proteasome. Mutant ataxin 3 can show impaired function leading to functional disruption of the UPS pathway [6] . Indeed, human ataxin-3 inhibits polyglutamine neurodegeneration in a Drosophila model of SCA3 by activating UPS [27] . Ataxins 1, 3, and 7 can be ubiquitinated and degraded by the proteasome. Indeed, the presence of extended polyQ tracts can impair the recognition and degradation of these proteins [6] . Alteration of the UPS can also be caused by caspase-dependent cleavage of proteasome subunits [6] . Impairment of the UPS system contributes to protein aggregation and leads, through caspase activation, to cell death.
Autophagy
Eukaryotic cells primarily use two distinct mechanisms for degradation: the proteasome and autophagy of aggregates by the lysosomes. Autophagy together with the UPS is necessary for the quality control system, which is responsible for the elimination of altered proteins inside the cells [28] .
Mammalian cells possess three types of autophagy: (i) macroautophagy; (ii) microautophagy: (iii) chaperone mediated autophagy. Macroautophagy is responsible of the degradation of entire regions of the cytosol, which begin surrounded and limited by a double membrane, forming an autophagosome. Next, the autophagosome fuses with the lysosome, which posses the enzymes for degradation [28] . This pathway is induced by stress conditions, in order to produce macromolecules and energy to the cells in low nutritional conditions. Alternatively, this pathway is activated to remove altered intracellular components [28] . Microautophagy has been mostly studied in yeast. This pathway targets and sequesters entire parts of the cytosol directly to the lysosomes. This pathway is involved in the degradation of organelles when they are not further required [28] . Chaperone-mediated autophagy (CMA) is responsible for the selective degradation of altered proteins. Proteins carrying a lysosomal targeting signal are recognized by chaperones and targeted to the lysosome surface, where they interact with a receptor and cross the lysosomal membrane to enter the lysosome and be degraded [29] . This pathway is activated by stress conditions, such as protracted cell starvation, in order to provide amino acids and energy to the cells. The specificity of CMA allows the selective removal of altered proteins without degrade the surrounding healthy proteins [28] .
The quality control system contribute first to the stabilization of unfolded proteins through chaperones. When the extent of unfolded proteins is elevated or there are cellular conditions blocking the refolding, misfolded proteins are degraded by the UPS or by autophagy. The UPS and CMA are unable to degrade aggregates, which are eliminated by macroautophagy [30] . Conversely, inhibition of the macroautophagy in neurons leads to the spontaneous formation of aggregates and neurodegeneration [31, 32] . The formation of aggregates induces the activation of macroautophagy, probably because of sequestration of the inhibitors of this pathway (such as mTor) into the aggregates [33] .
Interestingly, aggresome-forming proteins can also have a cytoprotective function, because they can accelerate degradation, as demonstrated in a cellular model of BSMA. Indeed, aggresomes are associated with lysosomal structures, leading to autophagy [34] . However, autophagy can exert either deleterious or protective effects depending on the specific situation and stage in the pathological process [30] . Previous studies suggest that UPS and autophagy are two distinct mechanisms of protein degradation. However, recent results demonstrated that these two pathways are connected. Indeed, inhibition of UPS induces autophagy. In agreement, genetic impairment of the autophagy system leads to cell death that correlate with increased ubiquitination. Thus, it seems that there is a compensatory interaction between UPS and autophagy [35] . Autophagy compensates impaired UPS in a Drosophila model of SCA [35] .
Autophagy compensation is HDAC6 dependent. HDAC6 is a deacetylase associated with microtubules and interacts with polyubiquitinated proteins. Indeed, overexpression of HDAC6 rescues UPS-associated neurodegeneration in a Drosophila model of SCA by inducing autophagy [35] . These results suggest that impaired autophagy during ageing can predispose to neurodegeneration by inducing the UPS [35] .
ER Stress
The Endoplasmic Reticulum (ER) regulates the synthesis, the correct folding, post-translational modifications and targeting of nascent proteins [36] . Alterations in the function or integrity of ER induce ER stress. Accumulation of unfolded proteins and calcium homeostasis inside ER causes ER stress and the activation of signaling pathways such as the unfolded protein response (UPR) [37] . UPR induces changes in the expression of heat shock proteins (Hsp), the degradation of misfolded proteins and inhibits protein synthesis to counteract the accumulation of unfolded proteins [37] .
When ER function is severely impaired, activation of pathways leading to cell death occurs [38] . Alterations in the UPS system can contribute to ER stress [37] . Briefly, induction to cell death converges to mitochondrial function, producing changes in membrane permeability and release of the cytochrome-c. There is an important cross talk between ER and mitochondria during the induction of cell death [38] . The cytochrome-c-dependent apoptotic pathway is activated by ER stress. Mitochondria dysfunction and reactive oxygen species (ROS) can also induce ER stress. ER stress plays a role also in PolyQ diseases, due to the presence of unfolded proteins in the ER [6] . mHtt alters calcium homeostasis in the cells and polyQ fragments are associated to Hsp70 and Hsp40, which induce ER stress [37] . Moreover, a loss of function of mHtt can be implicated in ER stress. Indeed, knock down of wild-type Htt by RNA interferences strongly affects ER morphology [39] .
In SCA3 is observed activation of Inositol-requiring kinase 1 (IRE1) after impairment of the UPS, showing the link between UPS and ER stress [39] . Moreover, activation of apoptosis signal-regulating kinase 1 (ASK1) is necessary for PolyQ-induced ER mediated apoptosis [40] . A further evidence of the role of ER stress is that polyQ fragments can activate in vitro the ER caspase 12 in the absence of caspase 8 and 3 activation [41] . SCA1 animal models show a decrement of proteins involved in calcium homeostasis and alterations of ER function leading to ER stress [6] .
Oxidative Stress
Neurodegenerative diseases present an increment of ROS production and altered mitochondrial function, which leads to activation of the caspase family of cysteine proteases that induce cell death. Moreover, various stimuli, such as perturbation in redox status, expression of misfolded proteins, altered glycation and glucose deprivation, overloading of products of polyunsaturated fatty acid peroxidation (Hydroxynonenals, HNE) or cholesterol oxidation and decomposition, can disrupt redox homeostasis, impose stress and subsequently lead to accumulation of unfolded or misfolded proteins in brain cells. There are evidences suggesting that altered energy metabolism contribute to excytotoxic processes, oxidative damage in HD. There are elevated levels of oxidative damage products in areas of degeneration in HD brain, and increased free radical production in animal models, suggesting that oxidative stress can be either a causative event, or a secondary constituent of the cell death cascade in the disease [42] . In HD is observed increased activation of caspase-3, which can cleave mHtt producing truncated forms of the protein that enter the nucleus. Accumulation of truncated mHtt in the nucleus interferes with gene expression by binding several transcription factors such as CREB binding protein and p53. It has been hypothesized a link between nuclear and mitochondrial effect of mHtt. Indeed, p53 regulates the expression of several mitochondrial genes. Thus, mHtt affects also mitochondrial gene expression by sequestering p53 in the nucleus [43] . mHtt affects also the trafficking of mitochondria, leading to mitochondrial dysfunction [44] . Indeed, neuronal dysfunction in HD striatum involves deficits in mitochondrial function and in Ca 2+ handling [45] .
Mutant ataxin 3 and 7 induces the recruitment of caspases in polyQ aggregates, leading to activation of caspase 3 and 9 and mitochondrial apoptotic pathways [6] .
Gene Expression Dysregulation
PolyQ mutant proteins can directly interact and sequester several transcription factors [46] . mHtt binds the transcriptional factor p53 and the transcriptional co-factor CREB binding protein (CBP). The association is polyQ-length dependent and leads to transcriptional repression [47] . Wildtype Htt is directly involved in the regulation of gene expression. Htt induces the expression of BDNF by binding and sequestering in the cytoplasm the silencer factor REST/ NRF. In HD the expression of BDNF is down-regulated because of reduced interaction between Htt and REST/NRF, which can enter the nucleus leading to BDNF transcriptional repression [47] . The nuclear localization of the histone deacetylase HDAC5 is increased in HD. HDAC5 interacts with HDAC3 inducing nuclear translocation of HDAC3. In HD, the increment of HDAC5-induced nuclear localization of HDAC3 leads to transcriptional repression [47] .
The Androgen Receptor (AR) regulates directly gene expression and interacts with several co-regulators such as CBP [48] . Indeed, mutant AR affects gene expression [48] .
Ataxin 1 is directly involved in transcriptional regulation by interacting with the co-repressors N-CoR/SMRT and INHT [47] . Moreover, wild-type ataxin1 interacts directly with HDAC3 and with the 14-3-3 family of proteins, which phosphorylate class II HDAC inducing HDAC cytoplasmic retention [47] . Thus, mutant ataxin 1 shows affected interaction with these proteins, leading to transcriptional dysregulation. Ataxin 3 is a transcriptional co-repressor by binding to CBP, p300 and P/CAF, which are involved in histone acetylation and gene expression activation. Ataxin 3 directly associates with histones and inhibits histone acetylation by CBP and p300, leading to transcriptional repression [47] . Ataxin 7 is a component of the transcriptional co-activator complex STAGA, composed by SPT3, TAF9, ADA, and GCN5 acetyltransferase [47] . Ataxin 7 mediates the interaction between STAGA and the transcription factor CRX (cone-rod homeobox), leading to activation of photoreceptor-specific genes [47] . Mutant ataxin 7 exerts a dominant negative effect that induces down regulation of photoreceptor-specific genes [47] .
In DRPLA, fragments of mutant atrophin 1 accumulate in the nucleus and interact with ETO in nuclear-matrix structures. This interaction sequesters N-CoR/mSIN3a/HDAC complex inside the matrix structure, leading to hypoacetylation and transcriptional repression [47] .
THERAPEUTIC COMPOUNDS AGAINST POLYQ DISEASES
Inhibitors of Aggregation
Several studies demonstrate the toxic function of protein aggregates in PolyQ diseases. For this reason a therapeutic strategy is the use of compounds able to inhibit the formation of aggregates. Chemical chaperones can be used to block inappropriate protein interactions and enhance the degradation of the disease protein. Indeed, benzothiazoles and Congo red induce a reduction of aggregates in the R6/2 mouse model of HD [48] .
Through the same mechanism, thioflavine S, chrysamine G and Direct Fast suppress protein aggregation both in vitro and in vivo [6] . The disaccharide threalose inhibits aggregation both in vitro and in vivo and induces a behavioral improvement in animal model of HD [49] . This compound decreases the formation of aggregates by stabilizing polyQcontaining proteins. Moreover, it has the great vantage of the oral administration [49] . Beneficial effects have been obtained by using compounds increasing protein stability, such as dimethylsulphoxide (DMSO), glycerol, and trimethylamine N-oxide [6] .
Biological agents are also able to inhibit protein aggregation. Indeed, antibodies against the polyQ region of Htt block aggregation and apoptosis in vitro [46] .
The enzyme transglutaminase enhances protein aggregation by cross-linking of the polyQ tracts. Indeed, we shown that transglutaminase catalyzes the formation of aggregates in vitro [50] . Cysteamine is a competitive inhibitor of transglutaminase and it has been used in HD animal models [46] . Both cystamine and cysteamine exert beneficial effects in a knock-in mice model of HD (STHdhQ111/HdhQ111). These compounds inhibit mitochondrial depolarization induced by a mitochondrial complex II inhibitor 3-NP [51] . However, cysteamine does not decrease aggregation formation in vivo [46] . On the contrary, cysteamine induces the expression of the heat shock protein HSJ1b, leading to stimulation of the secretory pathway and release of BDNF from the Golgi apparatus [52] . Moreover, some evidences are suggesting that cysteamine acts also by inhibiting caspases [46] .
Inhibitors of polyQ aggregates have been analyzed also to alleviate the symptoms of BSMA. The compound ASC-J9 inhibits polyQ aggregates in vitro and in vivo and ameliorates the symptoms in a mouse model of BSMA [48] . Inhibition of protein aggregation has been also used in vitro by inducing the heat shock protein with the compound geldamycin [46] .
Various strategies have been developed to screen small molecules as therapeutic agents for polyQ diseases in order to prevent aggregate formation. However, long polyQcontaining proteins are insoluble in water, leading to a difficult large-scale preparation necessary for the in vitro screening of aggregation inhibitors. A strategy used is to introduce a polyQ tract in a stable protein. Indeed, mice carrying a polyQ insertion in the hypoxanthine phophorybosiltransferase protein develop a late onset neurodegeneration [49] . Moreover, sperm whale myoglobin carrying a polyQ tract has a pathologic conformation similar to polyQ disease proteins and forms amyloid fibers [49] .
This chimera was used to screen in vitro small molecules able to inhibit the formation of aggregates. Trehalose was selected using this strategy. This drug was further evaluated in an animal model of HD, by oral administration. Indeed, trehalose induces an extended life span and improvement of the motor dysfunction [49] . Another system to screen for aggregation inhibitors in vitro consists in a cellular model expressing polyQ proteins fused to cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP). Self association and aggregation are measured by FRET, which occurs when an energy donor (CFP) transfers energy to an acceptor molecule (YFP) [53] . The selected compounds were further evaluated for the capability to inhibit toxicity in a Drosophila model of PolyQ disease [53] . This method provided the selection of 5 drugs with different function. Interestingly, inhibitors of signaling (EGFR, syk kinase, caspase 1) lead to decreased protein aggregation [53] .
A yeast system has also been used to screen small molecules able to inhibit the formation of aggregates. This model consists of a yeast strain expressing an N-terminal fragment of Htt carrying an extended polyQ (Htt-130Q). Using this method it has been selected a small molecule that strongly inhibits the formation of polyQ aggregates in vitro and also in vivo in a Drosophila model of HD [54] .
Induction of Autopahgy
Autophagy is involved in the degradation of polyQ proteins. Indeed, mutant proteins accumulate when cells were treated with different inhibitors acting at distinct stages of the autophagy-lysosome pathway. Induction of autophagy using rapamicin stimulates the clearance and reduces the formation of aggregates. This drug also reduces cell death in vitro [55] . It seems that rapamicin induces autophagy by inhibiting mTor pathway [6] .
Overexpression of HDAC6 rescues SCA symptoms in a Drosophila model of SCA by inducing autophagy, suggesting that induction of HDAC6 expression can be used as therapeutic strategy in polyQ diseases [35] .
Inhibitors of Caspase Activation, Apoptosis, and Oxidative Damage
Several polyQ proteins are substrate for caspase cleavage, leading to increased toxicity due to the truncated form [46] . HD patients show reduced glucose metabolism, leading to a decrement of ATP production that induces the production of free radicals and oxidative damage [46] . Inhibition of caspases can be beneficial by reducing toxicity and inhibiting apoptosis. The inhibitor zVAD-fmk leads to slower disease progression in HD animal models [46] . Inhibition of caspase 3 and 9 activation by the antibiotic minoclycline is also beneficial in vivo and decreases the symptom manifestation [46] . Other inhibitors of caspase activation have been used, such as CrmA and FADD DN [6] . Stabilization of mitochondria by the antioxidant tauroursodeoxycholic acid (TUDCA) leads to decreased striatal apoptosis and ameliorates behavioral deficit [46] . Stabilization of mitochondria is the pharmacological target of two other compounds: coenzyme Q10 and creatine [6] . Indeed, creatine added to the diet induces delayed striatal atrophy, improves survival and decreases aggregate formation in a mouse model of HD [56] . Creatine has been used in clinical trial, demonstrating that this drug is safe, tolerable and reduces serum 8-hydroxy-2'-deoxyguanosine (8OH2'dG) levels, which is a marker of oxidative DNA injury [56] .
Compounds to Restore Transcription
Dysregulation of gene expression has been observed in PolyQ diseases. Several of the polyQ disease proteins can interact and sequester transcription factors, which have acetyltransferase activity (HAT) [46] . Condensation of eukaryotic DNA in chromatin suppresses gene activity through the coiling of DNA on the surface of the nucleosome core and the folding of nucleosome assemblies, decreasing the accessibility to the transcriptional apparatus [58] . Deacetylation of histones by histone deacetylases (HDACs) might establish repressive chromatin. The family of HDACs consists of 17 isoforms grouped in 3 families [58] . On the contrary, histone and transcription factors acetylation by HAT is associated to the induction of "open" chromatin and activation of gene expression. CBP and p300 play a key role in this event because of their intrinsic HAT activity [58] . Overexpression of HATs can ameliorate polyQ toxicity both in vitro and in vivo [46] . Furthermore, mHtt expression in cell culture leads to a decrement of histone acetylation. Since the co-ordinate and opposite functions of HATs and HDACs regulate histone acetylation, inhibitors of the HDACs can compensate the effects due to HAT sequestration. HDAC inhibitors are beneficial in both mice and Drosophila models of HD [46] . Several HDAC inhibitors are currently in phase I-II clinical trials: phenylacetate, valproic acid, phenylbutyrate, depsipeptide, MS-257, and suberoyl anilide hydroxamic acid. Moreover, valproic acid and phenylbutyrate are FDA approved as therapeutic agents for other diseases [46] . Inhibitors specific for class III HDAC have been used, such as nicotinamide (vitamin B3). This compound blocks polyQ toxicity in a Drosophila model of SCA3 [47] . On the contrary, activation of class III HDAC by resvenatrol ameliorates polyQ toxicity in a C. elegans model of HD [47] . One explanation of these contradictory results is yet not available.
HDACs deacetylate not only histone, but also other proteins. HDAC6 interacts with dynein and regulates autophagy [46] . Moreover, HDACs deacetylate also p53 and Hsp90, which are involved in PolyQ diseases. Levels of p53 are elevated in HD and p53 regulates directly both wild type and mHtt expression. Deacetylation of p53 leads to p53 ubiquitination and degradation [47] . Hsp90 is involved in two different chaperone complexes: the first is a proteasome-targeting complex, containing Hsp70 and Hsp90; the other is a stabilizing complex formed by Cdc37 and p23. p23 is involved in the stabilization of AR, which is the disease protein in BSMA [47] . Mutant AR shows increased affinity for p23. Acetylated Hsp90 has less affinity for p23, leading to Hsp90 recruitment towards the proteasome-targeting complex. The inhibition of HDAC results in increased Hsp90 acetylation, which leads to increased degradation of the Hsp90 client proteins limiting the formation of aggregates [47] . Using an opposite mechanism, the Hsp90 inhibitor 17-AAG induces mutant AR degradation in a mouse model of BSMA. Indeed, 17-AAG inhibits the Hsp90/p23 complex that stabilizes mutant AR, increasing degradation of mutant AR [59] .
HMGB1/2 are sequestered in the nucleus by mHtt aggregates, leading to altered gene expression. Indeed, it has been shown that soluble HMGB1/2 are decreased in nuclei of neurons expressing mHtt. Overexpression of HMGB1 in neurons expressing either mHtt or mutant ataxin 1 results in reduced toxicity. Moreover, overexpression of HMGB1 ameliorates polyQ-induced toxicity in a Drosophila model of polyQ disease [60] .
Neurotrasmission and Excitotoxicity
The involvement of excitotoxicity in PolyQ diseases has been demonstrated. Brain injection of excitatory amino acids in mice brains produces both histological and behavioral manifestations of HD [46] . HD is characterized by increased vulnerability to receptor agonists and elevated levels of neurotransmitters, because mHtt affects both endocytosis and secretion [46] . Lamotrigine, a glutamate-release inhibitor, ameliorate the chorea in HD, but not the disease progression [46] .
The NMDA receptor antagonist ketamine was used, but it produced limited results against disease progression. NMDA receptor has a complex composition, physiology and kinetics. It is composed by NR1, NR2A-D subunits and occasionally by NR3A or B. NR2A and B can affect the age of onset of HD, leading to the necessity of a subunit-specific pharmacologic treatment. Moreover, the pharmacologic use of antagonist should maintain also the normal function and inhibits only the excess of activation. The compound memantine has these characteristics and ameliorate the disease progression of HD in clinical trial [46] .
Chronic administration of agonist of either mGluR2/3 or mGluR5 receptors in HD pre-symptomatic mice leads to increased survival and attenuates the other symptoms [46] . Furthermore, compounds blocking the A2A adenosine receptor and the cannabinoid CB1 receptor are beneficial in animal model of HD [46] . Acetazolamide alleviates the symptoms of SCA6. Drugs targeted to dopaminergic and cholinergic receptors are effective against tremor, bradykinesia or dystonia in SCA2 and SCA3 [6] . Baclofen, tizanadine or mimentine alleviates spasticity in SCAs, while botulinum toxin alleviates both dystonia and spasticity [6] . Benzodiazepines, beta-blockers or chronic thalamic stimulation decrease tremor in SCAs. Magnesium, chinine or mexiletine ameliorate muscle cramps. Gabapentin increases GABA concentration in the central nervous system, alleviating the symptoms of SCAs [6] .
Compounds for Trophic Support
Neurotrophic factors induce neuronal growth, differentiation and survival. Treatment with Nerve growth factor (NGF) gives contradictory results [46] . However, delivery of NGF by introduction of polymer encapsulated NGF shows beneficial effects in vivo [61] .
Other trophic factors have beneficial effects in animal models of polyQ diseases, such as ciliary neurotrophic factor (CNTF), glial-derived neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF). The delivery of these factors in HD animal models was induced with various methods: infusion, viral vectors and cell transplantation [46] . Mutant AR inhibits vascular endothelial growth factor (VEGF) expression. Indeed, VEGF treatment rescues neuronal apoptosis in a cellular model of BSMA [62] . Phase I clinical trial in HD patients demonstrates the safety of neurotrophin delivery [63] . SCA1 is characterized by transcriptional down-regulation of PP2 (serine/threonine protein phosphatase 2) in Purkinje cells. Insulin growth factor 1 (IGF-1) can be a potential therapeutic agent by inducing the PP2-regulated PI3K/Akt signaling pathway [64] .
Cell Transplantation
We previously discussed the relevance of cell transplantation systems in vivo for the delivery of trophic factors [65] . Epithelial cells of the choroid plexus (CP) secrete a cocktail of neurotrophic factors, and encapsulated CP transplants are neuroprotective in animal models of HD [66] . Moreover, the time in culture does not affect the viability of the cells and their ability to prevent neurodegeneration after transplantation [67] .
Cell-replacement therapies for polyQ diseases require the specific differentiation of multipotent neural stem cells before transplantation. Stable GABAergic neurons have been obtained from immortalized striatal neural stem cells line ST14A and they are suitable for transplantation in HD models [68] . Genetically engineered human neural stem cells have also been obtained, suitable for transplantation in patients [69] .
Several methods have been developed for the transplantation of cells. Transplantation of neuronal stem cells has been carried out directly in the striatum of HD patients and animal models. However, neural stem cells maintain the capability to migrate to sites of lesions. The migration capability has been analyzed after transplantations of the cells either from the ventricle or via a tail vein into a HD model. Neural stem cells are able to migrate to the striatum either from the ventricle or from the circulation [70] . Rat embryonic neural progenitors transplanted in a rat model of HD are capable to survive, migrate and differentiate into both neurons and glia. Although these cells are able to enhance metabolic function, they does not restore the complex neuronal circuitry [71] . On the contrary, post-mortem analysis of a patient subjected to transplantation of human fetal striatal tissue demonstrated that the transplant develops the appropriate neuronal connections. Although inflammation of tissue rejection did not occur, there was not an evident clinical benefit [72] . Actually, another clinical trial demonstrates that cell transplantation improves cognitive and motor function in three of five patients treated [73, 74] . Several studies hypothesize that neuronal precursors derived from fetal striatum may have a greater capacity than primary fetal striatum to project to the striatal target areas. On the contrary, it has demonstrated that fetal neural precursors produce grafts with richer axonal outgrowth than primary fetal grafts, and that the immunogenic background does not affect this event [75] .
Inactivation of the Disease Gene
Knock down of mHtt by RNA interferences (RNAi) has been carried out in cell models using the nonviral Sleeping Beauty transposon system. However, transcriptional down regulation was not mHtt-specific leading also to decreased wild-type Htt expression [76] . Since it is very difficult to knock down selectively only the mutant gene, a new strategy has been developed: down regulation of both wild type and mutant alleles by RNAi is followed by rescue of the wildtype gene expression by the insertion of a wild-type gene modified in order to escape the RNAi [77] .
Intraventricular injection of silencing RNA (siRNA) in the early postnatal period inhibits the expression of mHtt in a HD animal model. This treatment leads to prolonged survival and improves motor function [78] . Moreover, RNAi carried out in HD animal models using adenoassociated virus shows beneficial effects, lowering the formation of aggregates and improving both behavioral and neuropathological symptoms [79, 80] .
RNAi was also performed in a conditional mice model of HD after the initial neuronal loss. Although neuronal loss is not reverted by the RNAi, mHtt knock down prevents further neuronal loss and induces fully recovery from the motor deficit. This study shows the efficacy of RNAi treatment also after the initial neuronal loss [81] .
Interestingly, it is beneficial also the RNAi strategy lowering the amount of proteins involved in mHtt-induced citotoxicity. Nuclear translocation of mHtt involves its association in a complex containing GAPDH and Siah1, an ubiquitin-E3-ligase. RNAi of either GAPDH or Siah1 reduces mHtt nuclear translocation in vitro [82] .
RNAi using adenoassociated virus shows beneficial effects also in a mice model of SCA1 [83] . Moreover, treatment with siRNA against various CAG-length repeat inhibits toxicity in a cell model of BSMA [84] .
Anti-Inflammatory Agents
Inflammation seems to be involved in the pathogenesis of HD. Indeed, animal models of HD show increased expression of genes associated with inflammation [85] . Minocycline, which inhibits microglia activation, has neuroprotective effects in mice models of HD. On the contrary, drugs affecting cycloxygenase 1 and 2 have no effects in HD animal models [86] . However, the anti-inflammatory BN82451 reduces brain atrophy, ventricular enlargement, and neuronal intranuclear aggregates in HD animal models [87] .
Treatments of Diabetes in HD
Both HD patients and animal models show endocrine and metabolic dysfunction as consequence of impaired hypothalamic function [2] . Diabetes frequently develops in HD patients and animal models [88] . HD mice models are hyperglycemic and show a strong reduction of insulin secretion. They also present mHtt aggregates in peripheral tissues [88] . These animals have decreased beta-island mass and low pancreatic insulin content [88] . Both gene expression and exocytosis of insulin are impaired in HD animal models [88, 89] . Glibenclamide, a compound that induces insulin exocytosis, is beneficial for diabetes treatment in animal models of HD. Oppositely, rosiglitazone, which induces sensitization to insulin, has no effects. These data further support the hypothesis that diabetes in HD is caused by impaired insulin secretion and not by insulin resistance [90] . Interestingly, metformin, an anti-diabetes drug, prolonged the survival and decreases the hind limb clasping of male HD mice. Con-versely, this compound is not effective in female HD mice [91] . Moreover, DNA vaccination with a DNA fragment encoding the N-terminal of mutant [82] prevents diabetes development in a mice model of HD [92] .
CONCLUSIONS
HD and other polyglutamine diseases are due to expanded CAG repeats that encode glutamine (Q) in the disease proteins. Beyond a threshold length, polyQ expansion confers a novel toxic property that increases with longer repeats. Several models of pathogenesis are described in polyQ diseases: 1.Perturbations in protein homeostasis; 2. Aberrant processing of proteins; 3. Dysregulation of gene expression; 4. Abnormal trafficking; 5. Impaired energetics, excitotoxicity. All pathogenic mechanisms involve both a gain-offunction of mutant protein as well as a loss-of-function of the wild type protein, because of gene dosage and aggregation together with the mutant form. So, thorough analysis of these molecular and biochemical events, assessing the validity of candidate mechanisms, provides a means to identify effective therapeutic strategies for cellular repair.
Furthermore, the increasing availability of animal models allows not only to investigate the disease mechanisms in different polyQ diseases but also to screen and test potential therapeutic drugs in the promising area of neurotherapeutics. Indeed, there are several drugs that show efficacy in various models of different polyQ diseases. A lot of analyzed compounds are FDA approved and used as therapeutic agents for other diseases. Besides, there are new tools, such as gene silencing using gene therapy or cell transplantation, or in vivo and ex vivo gene therapy for delivery of neuroprotective growth factor molecules, which are now available for new therapeutic approach. Moreover, functional restoration through neuronal replacement probably could be combined with neuroprotective strategies for optimum clinical benefit. In fact, the combination of in vivo drug delivery and replacement of lost cells through transplantation may constitute the ideal therapeutic strategy to slow ongoing degeneration and promote restoration of functional circuitry. Further understanding of mechanisms regulating protein processing, aggregation and clearance systems, as well as comprehension of toxic effects of misfolded neurodegenerative disease proteins, will facilitate development of rationally designed therapies to treat and prevent these disorders.
